Alexandre Lourenço – ECCO 2019 European Cancer Summit
It was a privilege to meet Alexandre Lourenço, President of the Portuguese Association of Hospital Managers, at the ECCO 2019 European Cancer Summit in Brussels to discuss his expert opinion on how we can introduce novel therapies into use in a sustainable way.
1. To what extent is access to innovative cancer treatments limited in Portugal and is there a similar issue in other European nations? (0:08)
2. Is restricted access to some cancer treatments resulting in poor patient outcomes, increased morbidity and earlier deaths? (0:44)
3. Treatments such as chimeric antigen receptor (CAR) T-cells are highly effective in the treatment of some cancers. Could access to this and other novel treatments be increased through increased funding and/or improved technologies? (1:19)
4. Can you describe the key aims of the Primary Care P4P initiative in Portugal and how it could improve primary care in cancer? (1:50)
5. The Association of European Cancer Leagues (ECL) Access to Medicines Taskforce and other organisations aim to improve the availability of new cancer treatments. What progress have these organisations made towards this goal and what remains to be done? (3:00)
Alexandre Lourenço has no conflicts of interest to declare in relation to this video.
Filmed in partnership with the European CanCer Organisation at the ECCO 2019 European Cancer Summit in Brussels, Belgium.
Share this Video
Related Videos In Policy
Helena Ullgren: PrEvCan | Focus on alcohol and cancer prevention
The European Code Against Cancer (ECAC) recommends that if you drink alcohol of any type you should limit your intake and that not drinking alcohol is best for cancer prevention. This March, the PrEvCan campaign, spearheaded by EONS to promote cancer prevention across Europe, is bringing attention to the link between alcohol consumption and cancer […]
Pompiliu Piso: ESSO Oncopolicy – cross-multidisciplinary training in oncology at the EU level (Part 2)
The European Society of Surgical Oncology (ESSO), along with other cancer-related European societies, supported the proposal for cross-multidisciplinary training in oncology at the EU level. It was a pleasure to talk with Prof. Pompiliu Piso (Hospital Barmherzige Brueder, Regensburg, Germany) to discuss how cross-multidisciplinary training would affect cancer care in Europe and the other initiatives […]
Pompiliu Piso: ESSO’s open letter recognizing surgical oncology as a specialist discipline in the EU (Part 1)
The European Society of Surgical Oncology (ESSO) recently released an open letter urging the European Commission to recognise surgical oncology as a specialist discipline in the EU, entitled ‘Time to act: Maximizing the benefits of surgical oncology for cancer patients in Europe‘. touchONCOLOGY were delighted to catch up with Prof. Pompiliu Piso (Hospital Barmherzige Brueder, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!